Key statistics
As of last trade, Catalyst Pharmaceuticals Inc (CPRX:NAQ) traded at 20.74, 35.20% above the 52 week low of 15.34 set on Aug 05, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 21.71 |
---|---|
High | 21.78 |
Low | 20.60 |
Bid | 20.73 |
Offer | 20.75 |
Previous close | 21.62 |
Average volume | 1.30m |
---|---|
Shares outstanding | 121.98m |
Free float | 112.14m |
P/E (TTM) | 13.77 |
Market cap | 2.64bn USD |
EPS (TTM) | 1.57 USD |
Data delayed at least 15 minutes, as of Jul 15 2025 20:28 BST.
More ▼
- Catalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer
- Catalyst Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Provides Business Update
- Catalyst Pharmaceuticals to Participate in the BofA Securities Health Care Conference 2025
- Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025
- Catalyst Pharmaceuticals Announces Health Canada’s Acceptance of AGAMREE® New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals
- Catalyst Pharmaceuticals to Participate in the Barclays 27th Annual Global Healthcare Conference
- Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
- Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025
- Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2025 List of America's Most Successful Mid-Cap Companies
- Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan
More ▼